Carprodyl Quadri 50 mg Tablets for Dogs

Special precautions for use in animals
Use in aged dogs, may involve additional risk. If such a use cannot be avoided,

Revised: September 2025
AN: 01712/2025
dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a
potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of
inflammatory conditions associated with bacterial infection, appropriate
concurrent antimicrobial therapy should be instigated.
As with other NSAIDs, photodermatitis during treatment with carprofen has been
observed in laboratory animals and in humans. These skin reactions have never
been observed in dogs.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Due to the good palatability of the tablet, they should be stored in a safe place
out of the reach of animals. Intake of dose exceeding the recommended number
of tablets may lead to severe adverse effects. If this is the case, seek veterinary
assistance immediately.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet to the physician.
Wash hands after handling the product.
Special precautions for the protection of the environment
Not applicable
Other precautions
Not applicable.
4.6 Adverse reactions (frequency and seriousness)
Dog
Rare
(1 to 10 animals / 10,000
animals treated):
Renal disorder
Hepatic disorder
1,3
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Vomiting
, Soft stool/Diarrhoea
, Blood in faeces
Appetite loss
, Lethargy
1
As with other NSAIDs
Typical undesirable effects associated with NSAIDs, these adverse reactions
generally occur within the first treatment week and are in most cases transient
and disappear following termination of the treatment but in very rare cases may
be serious or fatal.
Idiosyncratic effects

Revised: September 2025
AN: 01712/2025
If adverse reactions occur, use of the product should be stopped and the advice
of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system.
See the package leaflet for respective contact details.
4.7 Use during pregnancy, lactation or lay
Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic
effects of carprofen at doses close to the therapeutic dose. The safety of the
veterinary medicinal product has not been established during pregnancy and
lactation. Do not use in pregnant or lactating bitches.
For breeding animals, do not use during reproduction period.
4.8 Interaction with other medicinal products and other forms of interaction
Carprofen is highly bound to plasma proteins and compete with other highly
bound drugs, which can increase their respective toxic effects.
Do not use this veterinary medicinal drug concurrently with other NSAIDs or with
glucocorticoids.
Concurrent administration of potentially nephrotoxic drugs (e.g. aminogylcoside
antibiotics) should be avoided.
Refers also to section 4.5
4.9 Amount(s) to be administered and administration route
For oral administration.
4 mg carprofen per kg bodyweight per day.
An initial dose of 4 mg carprofen per kg bodyweight per day given as a single
daily

dose. The analgesic effect from each dose persists for at least 12 hours.
The daily dose may be reduced, subject to clinical response.
Duration of treatment will be dependant upon the response seen. Long term
treatment should be under regular veterinary supervision.
To extend analgesic and anti-inflammatory cover post-operatively parenteral
pre- operative treatment with an injectable carprofen may be followed with
carprofen tablets at 4 mg/kg/day for 5 days.
Do not exceed the stated dose.
The breakability method is the following: Put the tablet on a plain surface, with
its scored side facing the surface (convex face up).
With the tip of forefinger, exert a slight vertical pressure on the middle of the
tablet to break it in its width into halves. In order to obtain quarters, then exert a
slight pressure on the middle of one half with forefinger to break it in its length.

Revised: September 2025
AN: 01712/2025
The tablet is divisible and can be used as follows:Number of tablets per dayDogweight (kg) ¼> 3-< 6 ½≥ 6-< 9 ¾≥ 9-< 12.5 1≥ 12.5-< 15.5 1 ¼≥ 15.5-< 18.5 1 ½≥ 18.5-< 21.5 1 ¾≥ 21.5-< 25 2≥ 25-< 28 2 ¼≥ 28-< 31 2 ½≥ 31-< 34 2 ¾≥ 34-< 37 3≥ 37-< 40 3 ¼≥ 40-< 43 3 ½≥ 43-< 45
The tablets are flavoured, and are accepted by dogs, but they may be
administered directly in the mouth of the dog or added to food if necessary.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Bibliographic data report that carprofen is well tolerated in dogs at twice the
recommended dosage for 42 days.
Doses up to 3 times the recommended dose are reported to be without adverse
effects.
There is no specific antidote to carprofen but general supportive therapy as applied to
clinical overdose with NSAIDs should be applied.
4.11 Withdrawal period(s)
No applicable.
5.